Analysts Issue Forecasts for YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research note issued to investors on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.75) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.66) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($0.94) EPS.

Several other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. BMO Capital Markets dropped their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Finally, Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Trading Down 2.7 %

NASDAQ YMAB opened at $10.26 on Monday. The company has a market cap of $459.54 million, a P/E ratio of -19.00 and a beta of 0.61. Y-mAbs Therapeutics has a 1 year low of $6.09 and a 1 year high of $20.90. The company has a fifty day simple moving average of $13.18 and a 200 day simple moving average of $12.75.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the firm earned ($0.18) EPS.

Insider Activity

In other news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $133,000. SG Americas Securities LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $178,000. Finally, Empire Financial Management Company LLC bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at about $210,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.